StageCorporate Majority | Acquired
Missing: CanChew Biotechnologies's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: CanChew Biotechnologies's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing CanChew Biotechnologies
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
CanChew Biotechnologies is included in 1 Expert Collection, including Cannabis.
These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.
Latest CanChew Biotechnologies News
Aug 3, 2015
Stuart Titus states: "MJNA and the new leadership has recognized the value of the wonderful leadership that the AXIM team provides. Alongside the new relationship with CanChew Biotechnologies and their patent on chewing gum and cannabinoids - the promise for significant IP, significant new products and pharmaceutical development exists. MJNA salutes and supports the team led by Dr. Anastassov in their clinical efforts and believes their delivery method for cannabinoids may provide a well-accepted and therapeutically improved delivery for cannabinoid-based pain medication, via the MedChew clinical trials ongoing in Europe . Recent FDA warnings have shown additional potential side effects from traditional NSAID medications - thus the MedChew trials are quite timely and well-needed. In fact, the FDA The Netherlands asked AXIM to specifically carry on these well-needed trials. Although MJNA and our team are not directly involved with these efforts, nonetheless, we strongly support any and all studies for safety and efficacy that the AXIM team is involved with. At MJNA we feel that further research will show the full potential for cannabinoids to the world of medicine - just as many anecdotal stories have shown with the botanical formulations available today. " About : AXIM Biotechnologies (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein. LEGAL DISCLOSURE AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products. North American Address:
CanChew Biotechnologies Frequently Asked Questions (FAQ)
What is CanChew Biotechnologies's latest funding round?
CanChew Biotechnologies's latest funding round is Corporate Majority.
Who are the investors of CanChew Biotechnologies?
Investors of CanChew Biotechnologies include Medical Marijuana.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.